IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models

Justin Yu,Jacob Gadwa,Richard B. Ross,Michael Knitz,Laurel B. Darragh,Khalid N. M. Abdelazeem,Jessica Beynor,Brooke Neupert,Alexander Nguyen,Diemmy Nguyen,Nicholas Olimpo,Sophia Corbo,Benjamin Van Court,Angelo D’Alessandro,Anthony Saviola,Sana D. Karam,Karam, Sana D.

DOI: https://doi.org/10.1007/s00262-024-03664-y

IF: 6.63

2024-03-31

Cancer Immunology Immunotherapy

Abstract:Clinically approved head and neck squamous cell carcinoma (HNSCC) immunotherapies manipulate the immune checkpoint blockade (ICB) axis but have had limited success outside of recurrent/metastatic disease. Interleukin-7 (IL7) has been shown to be essential for effector T-cell survival, activation, and proliferation. Here, we show that IL7 in combination with radiotherapy (RT) is effective in activating CD8 + T-cells for reducing tumor growth. Our studies were conducted using both human papillomavirus related and unrelated orthotopic HNSCC murine models. Immune populations from the tumor, draining lymph nodes, and blood were compared between treatment groups and controls using flow cytometry, proteomics, immunofluorescence staining, and RNA sequencing. Treatment with RT and IL7 (RT + IL7) resulted in significant tumor growth reduction, high CD8 T-cell tumor infiltration, and increased proliferation of T-cell progenitors in the bone marrow. IL7 also expanded a memory-like subpopulation of CD8 T-cells. These results indicate that IL7 in combination with RT can serve as an effective immunotherapy strategy outside of the conventional ICB axis to drive the antitumor activity of CD8 T-cells.

oncology,immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that in head and neck squamous cell carcinoma (HNSCC), the current immunotherapies, especially the traditional immune checkpoint blockade axes for recurrent and metastatic diseases, such as the PD1/PD - L1 pathway, have limited efficacy. The researchers explored activating the memory T - cell response by combining interleukin - 7 (IL7) with radiotherapy (RT) to improve the treatment effect in the HNSCC model. Specifically, the study aimed to evaluate whether IL7 can effectively activate CD8+ T cells, reduce tumor growth, and improve survival rate when used in combination with radiotherapy, without increasing the infiltration of regulatory T cells (Tregs) into the tumor microenvironment (TME). In addition, the study also explored the impact of this combined treatment method on the development of T - cell precursors in the bone marrow.